These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27067341)

  • 1. Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus.
    Gallego I; Sheldon J; Moreno E; Gregori J; Quer J; Esteban JI; Rice CM; Domingo E; Perales C
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3786-93. PubMed ID: 27067341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
    Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
    Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
    Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
    Ramirez S; Mikkelsen LS; Gottwein JM; Bukh J
    Gastroenterology; 2016 Nov; 151(5):973-985.e2. PubMed ID: 27453546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.
    Leumi S; Guo M; Lu J; Wang Z; Gan T; Han L; Ngari J; Tong Y; Xiang X; Xie Q; Wang L; Zhong J
    Antiviral Res; 2022 Jan; 197():105224. PubMed ID: 34864126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6.
    Xu S; Doehle B; Rajyaguru S; Han B; Barauskas O; Feng J; Perry J; Dvory-Sobol H; Svarovskaia ES; Miller MD; Mo H
    Antivir Ther; 2017; 22(7):587-597. PubMed ID: 28248189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
    Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.
    Pham LV; Pedersen MS; Fahnøe U; Fernandez-Antunez C; Humes D; Schønning K; Ramirez S; Bukh J
    Gut; 2022 Mar; 71(3):627-642. PubMed ID: 33833066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
    J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects.
    Han B; Martin R; Xu S; Parvangada A; Svarovskaia ES; Mo H; Dvory-Sobol H
    Antiviral Res; 2019 Oct; 170():104574. PubMed ID: 31394118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
    Di Maio VC; Cento V; Lenci I; Aragri M; Rossi P; Barbaliscia S; Melis M; Verucchi G; Magni CF; Teti E; Bertoli A; Antonucci F; Bellocchi MC; Micheli V; Masetti C; Landonio S; Francioso S; Santopaolo F; Pellicelli AM; Calvaruso V; Gianserra L; Siciliano M; Romagnoli D; Cozzolongo R; Grieco A; Vecchiet J; Morisco F; Merli M; Brancaccio G; Di Biagio A; Loggi E; Mastroianni CM; Pace Palitti V; Tarquini P; Puoti M; Taliani G; Sarmati L; Picciotto A; Vullo V; Caporaso N; Paoloni M; Pasquazzi C; Rizzardini G; Parruti G; Craxì A; Babudieri S; Andreoni M; Angelico M; Perno CF; Ceccherini-Silberstein F;
    Liver Int; 2017 Apr; 37(4):514-528. PubMed ID: 28105744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of Sofosbuvir-resistant mutations of hepatitis C virus genotype 3a replicon.
    Ngari JW; Leumi S; Han L; Liu C; Tong Y; Zhong J
    J Med Virol; 2023 Dec; 95(12):e29290. PubMed ID: 38102947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.
    Di Maio VC; Cento V; Mirabelli C; Artese A; Costa G; Alcaro S; Perno CF; Ceccherini-Silberstein F
    Antimicrob Agents Chemother; 2014 May; 58(5):2781-97. PubMed ID: 24590484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
    Fernandes Campos GR; Ward J; Chen S; Bittar C; Vilela Rodrigues JP; Martinelli ALC; Souza FF; Pereira LRL; Rahal P; Harris M
    J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33141008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV.
    Peres-da-Silva A; Brandão-Mello CE; Lampe E
    Antivir Ther; 2017; 22(5):447-451. PubMed ID: 28085003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing.
    Abe H; Hayes CN; Hiraga N; Imamura M; Tsuge M; Miki D; Takahashi S; Ochi H; Chayama K
    Am J Gastroenterol; 2013 Sep; 108(9):1464-72. PubMed ID: 23896953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.
    Costantino A; Spada E; Equestre M; Bruni R; Tritarelli E; Coppola N; Sagnelli C; Sagnelli E; Ciccaglione AR
    Virol J; 2015 Nov; 12():186. PubMed ID: 26577836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells.
    Wolfisberg R; Holmbeck K; Nielsen L; Kapoor A; Rice CM; Bukh J; Scheel TKH
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31292246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.
    Hedskog C; Dvory-Sobol H; Gontcharova V; Martin R; Ouyang W; Han B; Gane EJ; Brainard D; Hyland RH; Miller MD; Mo H; Svarovskaia E
    J Viral Hepat; 2015 Nov; 22(11):871-81. PubMed ID: 25784085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.